The company announced today the production of a vaccine candidate for the recently emerged H7N9 influenza virus (first appeared in China) by an independent third-party laboratory using its BioLaunch platform. This accomplishment took only 21 days as measured from the initial antigen sequence information to purification of recombinant protein.

iBio's BioLaunch platform eliminates the need to culture cells under sterile conditions, removes uncertainty about yield consistency for large production volumes, and, subject to regulatory approval, can possibly deliver vaccine doses for emergency use against a pandemic or bio-terrorism threat. The platform has been used successfully before to produce vaccine-quality antigens associated with a range of influenza strains including H7N7, H5N1, H3N2, H1N1, and a variety of influenza B strains.

The company's iBioLaunch platform is a step ahead of current conventional approaches. It eliminates the months involved in the development and production of regular vaccines for viruses. Patient care now often involves only isolation of patients and supportive care. For further information about iBio and its technologies, please visit ibioinc.com.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

First-quarter revenues were $2.5 million over revenues of $1.1 million recorded for the prior year period.

Gross profit was $351,396 with a net loss of $649,143, which was in part attributed to charges of $250,616 for stock-based compensation and $241,376 in financing related costs totaling $491,992 in non-cash write-offs.

Labor SMART increased its branches in the first quarter by 33 percent, expanding from six branches to eight and contributing to an overall branch increase of 133 percent year to date. Subsequently, the company's first-quarter expenses attributed to staff payroll increased as training continues for its expansion team in 2013.

"We are extremely pleased with the exponential growth in top-line revenues and branch operations that we have been able to produce so far in 2013," Ryan Schadel, Labor SMART's CEO, stated in the press release. "We invested heavily in our people and our infrastructure during the first quarter and these investments are paying off handsomely now and into the future as we prepare for our next leg of expansion."

For more information visit laborsmart.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

Due to the rapidly changing face of payment technologies and customer demands, 3Pea built the PaySign® platform on modern cross-platform architecture and designed it to be highly flexible, scalable, and customizable. PaySign® will allow the company to significantly expand its operational capabilities, allowing 3Pea to enter new markets within the payments processing space.

The payment processing platform was designed to easily incorporate new payment technologies and applications as they evolve, allowing 3Pea to remain at the forefront of payment innovation. PaySign® also provides flexibility and efficiencies that will allow the company to significantly reduce the time and cost related to card program development and customization, resulting in increasing operating margins. The PaySign® platform was created with the ability to facilitate EMV (EuroPay, MasterCard, and Visa) smart card payment system (Chip and PIN) payments on a global basis.

PaySign®, in development for several years, meets PCI-DSS 2.0 compliance standards and was part of the company's most recent successful PCI-DSS audit. The audit, underscoring 3Pea's continuing commitment to maintaining the highest level of data security standards and compliance, certified 3Pea as a Level 1 Service Provider (Issuer), Gateway/Switch, Prepaid Services, and Issuer Processing Provider.

Additionally, PaySign® Platform will be integral in the development, launch, and support of the PaySign® brand of prepaid debit cards, 3Pea's line of prepaid cards targeting the General Spend, Corporate, Government, and International markets.

Integrating rapid rendering and modern web technologies that has solid cross-browser support, the user interface for the platform's Card Management System (CMS) will simplify card program administration. The platform also boasts Interactive Voice Response (IVR) and two-way SMS messaging, which supports cardholder inquiries and card activation.

"We are extremely excited about the launch of our PaySign® platform and the growth opportunities it affords 3Pea as both a payments processor and prepaid debit card manager. We are confident in our ability to successfully enter key market verticals and broaden our prepaid debit card offerings," stated Mark Newcomer, President and CEO of 3Pea International. "We feel that the successful development and launch of the PaySign® platform is a defining moment for 3Pea."

For more information on 3Pea International, visit 3pea.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

• Dr. George Adams (CEO) is a scientist as well as a long-time entrepreneur and expert financier. Prior to VentriPoint, he was CEO of Amorfix Life Sciences, and continues as Chairman of Semova Corp., both publicly owned companies. Earlier, he was President and CEO of the UT Innovations Foundation, and has also held research and executive positions with Boston Scientific, Pfizer, Corvita Canada, the University of Ottawa, and others. He has been instrumental in founding over 30 companies who have raised $100 million, and has been Director of 10 venture capital funds and 10 startup companies. He has 124 scientific publications, and is a reviewer for major scientific journals, federal granting agencies, and others. Dr. Adams has accepted awards for World Economic Foundation Technology Pioneer, 2007, and TBI Company Of The Year, 2009.

• Ellen Briant (CFO) has 20 years of professional finance experience, with a focus on private placement and merger & acquisitions transactions to mid-market and startup companies. She has provided corporate financing advisory services at Spire Sharwood, and was VP & Director of the Private Placement Group for Deloitte & Touche, arranging debt financing and advisory services for various sized clients, including government entities. She was also part of the Corporate Banking Group at Scotiabank, and the Financial Services Audit Group of Ernst & Young.

• Amol Karnick (VP, Sales & Business Development) has over 18 years of medical imaging experience, including 7 years at GE Healthcare where he helped drive $150 million in imaging sales in addition to integrating 4 companies. He was the Chief Operating Officer for Sentinelle Medical, responsible for Engineering, Service, Manufacturing, and Regulatory Affairs, and was General Manager at Ultrasonix Medical where he grew sales through business development. He has experience working with multiple cultures around the world.

• Scott Ashley (VP, Research & Development) has 26 years of core operating system software development and project management, as well as first-line, second-line, and director experience. He was Director of Software Development for HP Integrity NonStop NS 16000 Server, managing over 80 developers, and was a key driving force across the Tandem NonStop Division.

• Eyal Schwartz (Chief Architect) has 16 years of experience leading various software development projects. He was a development leader at Microsoft in the Windows, MSN, and Entertainment divisions, and did lead design and development of a wide array of technologies. He is also the owner of 10 U.S. patents.

For additional information, visit VentriPoint.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

President and CEO of TAS, Mark Saxon (B.Sc. Geology), an 18-year exploration and resource geology veteran who is also a founding director over at Mawson Resources and manages their uranium projects across Europe (as VP Exploration), broke today's news to markets and called reception of the mining lease a major milestone for Tasman. Saxon was eager to thank staff and consultants who helped make this a reality, noting the rigorous social impact studies done thus far in order to fully highlight positive regional impact from the developments at Norra Karr. The lease comes in after considerable stakeholder consultation and while, as per standard practice for all such new mining leases, said stakeholders will have a five-week interval to appeal, this is a clear green light given how the extensive independent environmental/social impact assessment process played out.

Regular community meetings, several years of data compilation looking at flora/fauna (biogeochemistry of local plant life) and water quality in streams/lakes for the environmental baselines, study of lake, river, and soil sediments, even waste-rock and tailings composition analysis were done to bring TAS to this point. They even did the leaching analysis and made determinations about where to put future tailings, engaging local and regional government officials at every step, with zero impediments to project furtherance kicked up at any point during this in-depth research process.

The 100%-owned Norra Karr (1 claim of some 1,359 acres) is a premium REE site and one of only two NI 43-101 compliant resources in the EU, making the development a no brainer for the entire EU region from a strategic growth standpoint, especially amid REE curtailment of output by major global producer China at the start of 2013. The best part is TAS owns the only other such REE site outrightly as well, a sizeable hydrothermal (metasediment-associated), xenotime-rich heavy REE resource named Olesrum (also apatite, monazite, and minor allanite), just 62 miles or so east of Norra Karr, which has been validated by 24 holes of drilling to date. Norra Karr is very analogous to REE mines in Russia's Lovozero province and bears a striking geological resemblance to the rich REE, niobium, and zirconium well-known to be found in abundance there. Inferred Mineral Resource is 60.5M tonnes at 0.54% TREO (total RE oxides) and 1.72% ZrO2 (zirconium oxide), with 53.7% of the TREO being the higher value heavy rare earth oxide.

The economics here are delicious, with denser values for the key REEs dysprosium, neodymium, terbium, and yttrium making Norra Karr one of the biggest and most feasible projects among potential peers, especially considering the advantages of having infrastructure already in place and an easy-to-process mineral profile (ambient temperature pressure processing will suffice nicely). This is an REE bonanza in the heart of the EU (about 9 miles northeast of Granna, some 186 miles southwest of Stockholm) with superb access to markets and logistics (operating ports, power, road, rail, and even skilled personnel sources). The extremely short interval of time elapsed from initial discovery to application for the lease should tell markets everything they need to know about the advantages of operating in a mining friendly jurisdiction like this, where political stability, a long history of government working with industry, and a transparent Mining Act all contribute to promoting operational momentum for developers like TAS.

Saxon was happy to assert that Norra Karr can handle the EU's demand for REEs for some 40 years or so and couldn't help his pride over the fact that the supply security this project will create for EU industries will no doubt have a profound, long-term impact on European markets as a whole. With some 95% of much-needed REEs coming into EU markets from China, TAS is poised to deliver the high-tech metals that EU markets will require moving forward via a low-risk, stable locale where the deposit is also exceptionally low in radioactive content (under 15ppm uranium/thorium).

Learn more about Tasman Metals at TasmanMetals.com

Please see disclaimer on the QualityStocks website

:

http

://

disclaimer.qualitystocks.net

The company's Phytiva brand utilizes the unique and potent benefits of cannabinoids, the natural components found in the cannabis sativa L. plant, from which cannabis and hemp are produced. The company's formulations target not just the symptom, but the cause of critical ailments. Because the body responds extremely well to their properties, X-Change believes cannabinoids provide the ideal solution for better treatment and patient outcomes.

Respect for human life is a core value of the Phytiva brand, and X-Change believes that there are countless possibilities to be unleashed from the cornucopia of nature for good health and wellbeing. Phytiva uses the latest science and technology to study these possibilities with a key focus on making its carefully developed solutions accessible to all. First, all of Europe, the United States, and then beyond.

The staggering numbers of cases of HIV/AIDS, cancer, autoimmune disease, MRSA, diabetes, and a number of other ailments is X-Change's motivation to bring superior products to their respective markets, but the company is also targeting opportunities in the $350 billion personal care market. Leveraging its unique formulations and the branding abilities of its team, X-Change is well positioned to provide cannabinoid-based solutions to the mainstream market through multiple avenues.

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net